Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

• Status: Completed
• Trial end date: 2019-09-29
• Target enrollment: 0
• Participant gender: All

Summary

The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to high altitude. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Stanford University
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• Able to complete moderate hike at altitude

• Live at elevation < 4,000 ft

• Able to arrange own transportation to study site

• Available for full study duration (Friday night - Sunday morning)

Exclusion Criteria:

• Pregnancy

• Slept at altitude > 4,000 ft within 1 week of study

• Allergy to acetazolamide or sulfa drugs

• NSAIDs, acetazolamide, or corticosteroids within 48 hours prior to study start

• History of severe anemia, severe heart disease, advanced COPD/emphysema or sickle cell disease